Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Ovarian Cancer Pipeline Insight

DelveInsight’s, “Ovarian Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Ovarian Cancer Understanding

Ovarian Cancer: Overview

Ovarian Cancer is a type of cancer that begins in a woman’s ovaries – the small organs in the female reproductive system that create eggs. This kind of cancer can be difficult to detect because it often doesn’t cause any symptoms until later stages. Once found, Ovarian Cancer can be treated with chemotherapy and surgery to remove any tumors. As with most cancers, Ovarian Cancer becomes more common as a person gets older. The risk of Ovarian Cancer increases steeply from around 45 years and is greatest in those aged between 75 and 79 years. Between 5 and 15 out of 100 Ovarian Cancers (5 to 15%) are caused by an inherited faulty gene. Inherited genes that increase the risk of Ovarian Cancer include faulty versions of BRCA1 and BRCA2. Faults in these genes also increase the risk of breast cancer.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Ovarian Cancer.

Ovarian Cancer Emerging Drugs Chapters

This segment of the Ovarian Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Ovarian Cancer Emerging Drugs


Atezolizumab: Genentech

Atezolizumab is a humanized kappa immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster ovary cells. Atezolizumab was engineered to eliminate Fc-effector function via a single amino acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-glycosylated antibody that has minimal binding to Fc receptors and, consequently, eliminates detectable Fc-effector function and depletion of cells expressing programmed death−ligand 1 (PD-L1) in humans. Atezolizumab targets human PD-L1 and inhibits its interaction with its receptors, programmed death−1 (PD-1) and B7.1, both of which can provide inhibitory signals to T cells. The drug is currently in phase 3 of clinical trials for the treatment of Ovarian Cancer.


Tisotumab Vedotin: Genmab

Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. The drug is currently in phase 2 of clinical trials for the treatment of Ovarian Cancer.


Pembrolizumab: Merck

Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

Further product details are provided in the report……..

Ovarian Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Ovarian Cancer drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Ovarian Cancer

There are approx. 100+ key companies which are developing the therapies for Ovarian Cancer. The companies which have their Ovarian Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ovarian Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ovarian Cancer therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ovarian Cancer drugs.

Ovarian Cancer Report Insights

  • Ovarian Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Ovarian Cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Ovarian Cancer drugs?
  • How many Ovarian Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ovarian Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ovarian Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Ovarian Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Ovarian Cancer: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Ovarian Cancer – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Ovarian Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Ovarian Cancer Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Atezolizumab: Genentech

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Tisotumab Vedotin: Genmab

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Ovarian Cancer Key Companies

Ovarian Cancer Key Products

Ovarian Cancer- Unmet Needs

Ovarian Cancer- Market Drivers and Barriers

Ovarian Cancer- Future Perspectives and Conclusion

Ovarian Cancer Analyst Views

Ovarian Cancer Key Companies

Appendix

List of Table

Table 1: Total Products for Ovarian Cancer

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Ovarian Cancer

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Genentech

• Genmab

• AstraZeneca

• BioNumerik Pharmaceuticals

• On Target Laboratories

• Gilead Sciences

• Acerta Pharma

• MedImmune

• Chipscreen Biosciences

• Aravive, Inc.

• Allarity Therapeutics

• AB Science

• Syndax Pharmaceuticals

• Merck KGaA

• GlaxoSmithKline

• Aprea Therapeutics

• Verastem, Inc.

• Clovis Oncology

• CSPC ZhongQi Pharmaceutical

• Immunitor LLC

• Ellipses Pharma

• Impact Therapeutics, Inc.

• Eli Lilly and Company

• BeiGene

• Hoffmann-La Roche

• Apexigen

• Novartis Oncology

• Plexxikon

• Jiangxi Qingfeng Pharmaceutical Co. Ltd.

• PharmaMar

• Aprea Therapeutics

• VBL Therapeutics

• Tesaro, Inc.

• Cristal Therapeutics

• Bayer

• Pfizer

• Hrain Biotechnology Co., Ltd.

• Regeneron Pharmaceuticals

• DCPrime BV

• PTC Therapeutics

• AIM ImmunoTech Inc.

• Pharmicell Co., Ltd.

• Shattuck Labs, Inc.

• Laekna Limited

• Arcus Biosciences

• Verastem, Inc.

• Celsion

Forward to Friend

Need A Quote